托泊替康联合顺铂治疗广泛期小细胞肺癌

Effect of combined chemotherapy of topotecan and cisplatin on treatment of extensive stage small cell lung cancer

目的观察托泊替康联合顺铂治疗广泛期小细胞肺癌临床疗效及毒性反应。方法回顾性分析我科2010年1月至2012年6月收治的68例经病理证实的广泛期小细胞肺癌患者，其中TC组（托泊替康朋贝铂）36例，21例为初治患者，15例为复治患者，EP组（依托泊苷／顺铂）32例，均为初治患者。结果68例患者均可评价疗效，TC组一线治疗有效率明显高于二线治疗组（X^2=0．461，P=0．006），与EP组差异无统计学意义（X^=0．874，P=0．553）。TC组一线治疗患者与EP组患者生存期差异无统计学意义（P=0．847），显著长于二线治疗患者（P=0．021）。不良反应主要为骨髓抑制、消化道反应及脱发。结论托泊替康联合方案治疗广泛期小细胞肺癌安全有效。

Objective To study the efficacy and adverse effects of combined chemotherapy of topotecan and cisplatin in treatment of extensive stage small-cell lung cancer. Methods The elinicopathologic data of 68 patients with extensive stage small cell lung cancer proved by pathology in our department from January 2010 to June 2012 were analyzed. 21 patients were assigned to intravenous topotecan with cisplatin in first-line, 15 patients were assigned to intravenous topoteean with cisplatin in second-line,32 patients were assigned to intravenous etoposide with eisplatin in first-line. Results The effective rate in TC group in first-line was significantly higher than that in second-line （X^2 =0. 461, P = 0. 006）. There was no statistical significance in the effective rate between TC group in first-line and EP group （X^2= 0. 874, P=0. 553）. There was no statistical significance in overall survival between TC group in first-line and EP group （ P =0. 847）. The overall survival in TC group in first-line was longer than that in second-line （P = 0. 021）. The main adverse reactions were bone marrow suppression, gastrointestinal reactions and alopecia. Conclusions Combined chemotherapy of topotecan and cisplatin is effective for extensive stage small-cell lung cancer patients,drug-related toxicities are tolerable.